INTERIM REPORT FOR Q3 Ambu A/S, Baltorpbakken 13, DK-2750 Ballerup Registration no. 63644919 Financial highlights for Q3 INTERIM REPORT FOR Q3 In Q3 2025/26, Ambu delivered organic revenue growth of 10.3%, driven by strong performance in Endoscopy…
INTERIM REPORT
FOR Q3
Ambu A/S, Baltorpbakken 13, DK-2750 Ballerup
Registration no. 63644919
Financial highlights for Q3
INTERIM REPORT FOR Q3
In Q3 2025/26, Ambu delivered organic revenue growth of
10.3%, driven by strong performance in Endoscopy Solutions
growing 16.0% organically. Ambu’s continued operating leverage
and a positive effect from tariff reclaims resulted in a 13.5% EBIT
margin.
Organic revenue growth guidance for the 2025/26 financial year
is updated to around 10%, while EBIT margin guidance of 12-14%
is maintained.
“We delivered another strong quarter, with 16% growth in Endoscopy
Solutions and market share gains in all endoscopy areas, reinforcing
Ambu’s leadership in the conversion to single-use endoscopes. Growth
has accelerated in Respiratory, driven by strong momentum in
bronchoscopy and strong validation of our new SureSight video
laryngoscope portfolio. In the quarter, we expanded this with the
commercial launch of SureSight Mobile, highlighting our ability to
consistently bring differentiated innovation to health systems.
•
Revenue increased organically by 10.3% (12.0%) to DKK 1,640m (DKK 1,507m), with reported
growth of 8.8% (9.0%).
•
Endoscopy Solutions increased organically by 16.0% (15.9%). Respiratory posted 17.1% (11.2%)
organic growth, reflecting strong momentum, supported by the launch of SureSight Mobile.
Urology, ENT & GI grew 15.0% (20.8%) organically, with broad-based strength across the portfolio.
•
Anesthesia & Patient Monitoring posted an organic growth of 1.6% (6.4%), reflecting a good
performance in the face of high prior year comparables. Patient Monitoring continued to deliver
solid growth, while sales stabilized in Anesthesia.
•
Revenue growth was driven by solid organic growth in Europe and Rest of World, posting 10.2%
(11.5%) and 14.4% (7.9%), respectively. North America delivered growth of 9.7% (12.8%), with
strong performance in Endoscopy Solutions.
•
EBIT was DKK 221m (DKK 170m), with an EBIT margin of 13.5% (11.3%), reflecting continued
operating leverage and a positive effect from tariff reclaims, partly offset by investments in the
commercial organization.
•
Free cash flow (FCF) before acquisitions totaled DKK 154m (DKK 128m). This was driven by solid
operational performance alongside an improved working capital.
Business highlights for Q3
•
Completed full SureSight solution with launch of SureSight Mobile in the U.S. and UK.
•
Expanded neurology portfolio with Neuroline
I am pleased with the continued successful execution of our ZOOM
AHEAD strategy across the business as we realize the substantial
runway for growth. With innovation as a key focus area, I am excited
about the progress we are making in advancing new solutions across
all endoscopy areas, to realize our ambition of achieving global
endoscopy leadership.”
•
Recircle Program expanded with SureSight blades, now also made with bioplastics.
•
Expanded EndoIntelligence integration with hospital systems in key markets.
•
Earned validation of ‘best-in-class’ cybersecurity for aView
•
Continued investments in EndoIntelligence to drive differentiated, high-impact solutions.
•
Britt Meelby Jensen
Chief Executive Officer
Strategic AI partnerships initiated with leading U.S. medical institutions to accelerate
algorithm development for future bronchoscopy solutions.
•
Ambu UK recognized as ‘Best Single-Use Cystoscopy Platform in UK’ by MedTech Outlook.
•
Continued scaling of Mexico manufacturing facility to balance global footprint and manage
tariff costs.
•
First refunds received of IEEPA tariffs, with reclaim process ongoing.
•
Enhanced supply chain resilience via supplier diversification and strengthened partnerships.
•
‘A-’ CDP leadership rating, demonstrating strong sustainability focus across global supply chain.
•
New multinational survey of 456 endoscopy nurses published, showing that 62% experience
procedure delays due to endoscope availability, with 63% seeing single-use scopes as a solution.
Q3 2025/26 conference call
A conference call is broad cast live tomorrow, 26 August 2026 at 11:00 (CEST),
via Ambu.com/webcastQ32026. To ask questions during the Q&A session,
please register prior to the call via Ambu.com/conferencecallQ32026register.
Upon registration, you will receive an email with information to access the call.
The presentation can be downloaded at Ambu.com/presentations.
Company announcement no. 17 2025/26
|
25 August 2026
Cup MRI/CT solution in Patient Monitoring.
2 Advance and aBox
Updated 2025/26 financial guidance
•
•
Organic revenue growth: ~10%
EBIT margin: 12-14%1
1
We initially assumed a ~2%-pts tariff impact in FY 2025/26, but tariff refunds have reduced the expected headwind, supporting the
upper end of our 12-14% EBIT margin guidance. We continue to mitigate future tariff exposure through measures, including
investments in the Americas.
2
BUSINESS PERFORMANCE – IN BRIEF
Businesses and business groups
Growth composition
Revenue, DKKm
Endoscopy Solutions
Growth composition
Q3 2025/26
Split
Q3 2024/25
Organic
Currency
Reported
9M 2025/26
Split
9M 2024/25
Organic
Currency
Reported
1,046
64%
916
16.0%
-1.8%
14.2%
3,028
63%
2,755
14.8%
-4.9%
9.9%
514
32%
446
17.1%
-1.9%
15.2%
1,502
31%
1,387
12.5%
-4.2%
8.3%
532
32%
470
15.0%
-1.8%
13.2%
1,526
32%
1,368
17.1%
-5.6%
11.5%
594
298
36%
18%
591
304
1.6%
-0.4%
-1.1%
-1.6%
0.5%
-2.0%
1,743
884
37%
19%
1,816
948
-0.3%
-2.0%
-3.7%
-4.8%
-4.0%
-6.8%
296
18%
287
3.6%
-0.5%
3.1%
859
18%
868
1.4%
-2.4%
-1.0%
1,640
100%
1,507
10.3%
-1.5%
8.8%
4,771
100%
4,571
8.7%
-4.3%
4.4%
Anesthesia &
Patient Monitoring
Total
Geographies
Growth composition
Q3 2025/26
Split
Q3 2024/25
North America
802
49%
Europe
673
41%
Revenue, DKKm
Rest of World
Total
11.6%
Organic
Currency
750
9.7%
612
10.2%
Growth composition
Reported
9M 2025/26
Split
9M 2024/25
Organic
Currency
Reported
-2.8%
6.9%
2,333
49%
2,306
8.5%
-7.3%
1.2%
-0.2%
10.0%
1,988
42%
1,827
9.2%
-0.4%
8.8%
165
10%
145
14.4%
-0.6%
13.8%
450
9%
438
7.7%
-5.0%
2.7%
1,640
100%
1,507
10.3%
-1.5%
8.8%
4,771
100%
4,571
8.7%
-4.3%
4.4%
Respiratory
12m rolling
organic growth
Company announcement no. 17 2025/26
16.8%
|
25 August 2026
URO, ENT & GI
12m rolling
organic growth
Revenue
split by
businesses
Q3 2025/26
Endoscopy
Solutions
Anesthesia &
Patient Monitoring
64%
36%
3
FINANCIAL HIGHLIGHTS
Q3
Q3
9M
9M
FY
2025/26 2024/25 2025/26 2024/25 2024/25
DKKm
Income statement
Q3
Q3
9M
9M
FY
2025/26 2024/25 2025/26 2024/25 2024/25
Key figures and ratios
Revenue
1,640
1,507
4,771
4,571
6,037
Organic growth, %
10.3
12.0
8.7
14.3
13.1
Gross profit
975
887
2,870
2,754
3,633
Gross margin, %
59.5
58.9
60.2
60.2
60.2
EBITDA before special items
321
263
853
912
1,156
OPEX ratio, %
46.0
47.6
48.5
46.3
47.2
EBITDA margin b.s.i., %
19.6
17.5
17.9
20.0
19.1
EBIT margin b.s.i., %
13.5
11.3
11.7
13.9
13.0
EBITDA margin, %
19.6
17.5
17.9
20.0
19.1
EBIT margin, %
13.5
11.3
11.7
13.9
13.0
Tax rate, %
23
23
23
18
19
Return on equity, %
8
12
8
12
10
NIBD/EBITDA b.s.i.
-0.1
-0.2
-0.1
-0.2
-0.3
Equity ratio, %
79
80
79
80
79
Net working capital, % of revenue
21
21
21
21
21
Cash flow
Return on invested capital (ROIC), %
9
10
9
10
11
Cash flow from
operating activities (CFFO)
Average number of employees
5,595
5,218
5,498
5,202
5,233
331
237
692
542
791
Cash flow from
Investing activities (CFFI)
-177
-109
-421
-265
-384
Free cash flow (FCF)
154
128
271
277
407
CFFO, % of revenue
20
16
15
12
13
CFFI, % of revenue
-11
-8
-9
-6
-6
FCF, % of revenue
9
8
6
6
7
Cash conversion, %
48
49
32
30
35
Assets
7,775
7,396
7,775
7,396
7,675
Net working capital
1,326
1,266
1,326
1,266
1,238
Equity
6,168
5,905
6,168
5,905
6,035
Net interest-bearing debt
-126
-217
-126
-217
-319
Invested capital
6,042
5,688
6,042
5,688
5,716
Depreciation, amortization,
and impairment
-100
-93
-295
-275
-372
EBIT before special items
221
170
558
637
784
EBITDA
321
263
853
912
1,156
EBIT
221
170
558
637
784
Net financials
-18
-10
-45
-32
-29
Profit before tax
203
160
513
605
755
Net profit for the period
156
123
395
494
609
Special items
Share-related ratios (in DKK)
Market price per share
61
99
61
99
93
Earnings per share
0.59
0.46
1.49
1.85
2.29
Diluted earnings per share (EPS-D)
0.59
0.46
1.49
1.85
2.28
b.s.i. = before special items
Key figures and ratio definitions are consistent
with the ones applied in the Annual Report 2024/25.
Balance sheet
Company announcement no. 17 2025/26
|
25 August 2026
4
ENDOSCOPY
SOLUTIONS
ANESTHESIA &
PATIENT MONITORING
Ambu’s primary growth driver, Endoscopy Solutions,
accounted for 64% of the total revenue in Q3 2025/26
and delivered strong organic growth of 16.0% (15.9%).
Performance was driven by solid execution and
momentum across all endoscopy areas, reflecting
demand for Ambu’s innovative solutions and reinforcing
our leadership in driving the conversion from reusable to
single-use solutions.
Drivers of the quarter
The global endoscopy market remained strong,
supported by increasing procedure volumes and growing
adoption of single-use solutions, with Ambu leading the
transition from reusable to single-use endoscopes.
Continued investment in innovative solutions
Respiratory delivered organic revenue growth of 17.1%
(11.2%), reflecting accelerated momentum. Growth was
driven by increasing demand for our bronchoscopy
portfolio, which continues to improve clinical
performance and workflow efficiency, further supporting
single-use adoption as the future standard of care. In
addition, SureSight is becoming an important growth
driver, both directly and by supporting broader adoption
of our bronchoscopy portfolio. This underpins our
confidence in a strong near- to mid-term growth
trajectory for Respiratory and demonstrates our ability to
leverage our leadership position through full-solution
selling, backed by EndoIntelligence.
In the third quarter, Ambu launched SureSight Mobile,
further strengthening our Respiratory full-solution
offering. We are seeing strong customer feedback,
highlighting the value of a solution that supports
clinicians across a wide range of procedures.
Our full-solution strategy is expected to support the
ongoing conversion from reusable to single-use
endoscopes while further strengthening Ambu’s
differentiated position as the only provider offering a
comprehensive single-use endoscopy portfolio.
We continue to advance our EndoIntelligence platform,
expanding our innovation model beyond hardware
through software and AI capabilities that enhance image
quality, cybersecurity, and connectivity to electronic
health records. This supports workflow optimization at
hospitals and strengthens the value proposition of our
comprehensive endoscopy portfolio.
‘Urology, ENT & GI’ posted organic revenue growth of
15.0% (20.8%), reflecting strong underlying demand for
single-use solutions. Growth was largely driven by
cystoscopy and rhinolaryngology, where Ambu’s
solutions support higher patient throughput and align
well with the ongoing migration of procedures to
outpatient / ambulatory surgery center (ASC) settings.
16.0%
Urology delivered solid performance in a fast-growing
market, driven by very strong volume growth and a rising
number of decision-makers recognizing single-use as
standard of care. Cystoscopy momentum was strong,
supported by Ambu’s market leadership, while
ureteroscopy continued to be impacted by long sales
cycles as hospitals evaluate a growing number of singleuse solutions. We are confident in our ability to continue
to gain share through high-quality clinical performance,
EndoIntelligence, and further innovation. ENT gained
further traction, driven by healthcare providers' efforts to
reduce waiting lists through more outpatient and ASC
procedures, supported by the cost advantages of our
solutions. GI continued to build momentum, driven by
increasing customer adoption and strong purchase rates.
Q3 2025/26
organic growth
Company announcement no. 17 2025/26
|
25 August 2026
Anesthesia & Patient Monitoring accounted for 36% of Ambu’s
total revenue in Q3 2025/26, with organic growth of 1.6%
(6.4%). While the business returned to positive growth, there
continues to be a headwind from the annualization effect of
the commercial changes that we outlined in the Q2 2025/26
interim report. This was partly offset by solid commercial
execution and a market-leading portfolio that is supported by
strong brand recognition among customers.
Drivers of the quarter
The global healthcare market for anesthesiology, neurology,
and cardiology remained stable and growing, driven by
increasing procedure volumes and supported by demographic
trends and expanding access to healthcare.
Anesthesia posted -0.4% (3.9%) organic growth. As
mentioned previously, growth was impacted by price
increases implemented in prior years, which led to lower
volumes in Anesthesia in selected U.S. accounts operating
under non-exclusive contracts.
Patient Monitoring posted 3.6% (9.3%) organic growth.
Growth was driven by our market-leading portfolio. Especially,
neurology delivered strong growth, supported by an attractive
and growing market driven by increasing treatment of
neurological conditions.
We have expanded our neurology portfolio with FDA approval
and CE marking for Neuroline Cup MRI/CT-compatible EEG
electrodes. The solution will not have any impact for this
financial year, as commercialization begins at the start of next
year. The launch will support the 3-5% growth in Anesthesia &
Patient Monitoring throughout the strategy period.
1.6%
Q3 2025/26
organic growth
5
SUSTAINABILITY UPDATE
Sustainability in deeply integrated in Ambu’s strategy, business processes, and value
chain. At the same time, we are committed to helping customers reduce waste and
decarbonize. Our sustainability focus is centered on three key levers: take-back and
recycling program, circular products and packaging, and net-zero emissions.
Take-back and recycling program
In Q3, we expanded our take-back and recycling program, Recircle, with blades from our
SureSight video laryngoscope solution. With the addition of SureSight blades, we
continued to broaden our recycling offering across clinical practice. This supports our
goal of helping hospitals manage their environmental impact more consistently as part of
day-to-day operations, without adding complexity to clinical workflows. The Ambu
Recircle program is currently active across the U.S., France, Germany, and the UK, at ~50
hospital sites and in 140+ clinical departments.
During the quarter, we also progressed our controlled pilot deployments and continued
to evaluate potential commercialization models.
Circular products and packaging
In Q3, Ambu completed the transition of SureSight video laryngoscope blades to bioplastics. All blades across the portfolio, comprising 10 different sizes, are now produced
using bioplastics. Expanding our use of bioplastics beyond endoscopes further
strengthens Ambu's position as a sustainability leader in the MedTech industry.
Ambu is committed to operating responsibly and approaching net-zero emissions in
collaboration with suppliers, customers, and other partners. To deliver on our near-term
carbon reduction targets for Scope 1, 2, and 3 greenhouse gas emissions*, we are
executing on our plan, which includes:
For targets encompassing Ambu’s facilities (Scope 1 and Scope 2), we will expand the
use of renewable energy and reduce the energy consumption through a combination
of Renewable Energy Certificates (RECs), Power Purchase Agreements (PPAs), and
investments in installation of renewable power at our production sites.
•
For targets attributed to Ambu’s entire value chain (Scope 3), we are committed to
engaging with suppliers to further safeguard our sustainable transformation.
•
Ambu has officially made a commitment to the official SBTI net-zero target, and we are
preparing for data submission to SBTI.
- Scope 1 includes greenhouse gas emissions occurring from activities under Ambu’s direct control in sources that are
owned or controlled by Ambu. Scope 2 refers to indirect greenhouse gas emissions caused by the energy Ambu
purchases, such as electricity and district heating. Scope 3 reflects indirect greenhouse gas emissions – not included in
Scope 2 – that occur in our value chain, including both upstream and downstream emissions.
Company announcement no. 17 2025/26
9M
2025/26
9M
2024/25
Change
Recycled waste, % of total waste
53%
44%
18%
Waste, per tonne finished goods
0.28
0.30
-8%
CO2e** per tonne finished goods
Energy (GJ) per tonne finished goods
0.94
0.94
0%
17
18
-9%
** including Scope 1 and 2
Waste management
Waste management remains a key priority across Ambu’s manufacturing facilities
and offices. For the first 9 months, Ambu achieved an 18% increase in the proportion
of recycled waste compared to the same period last year. This improvement was
driven by the reclassification of certain waste treatments from “recovered” to
“recycled,” as well as the introduction of new production lines that generate higher
volumes of recyclable waste. Improved material use contributed to an 8% reduction in
waste generated per tonne of finished goods.
CO2 reduction
Net-zero emissions
•
SUSTAINABILITY HIGHLIGHTS
|
25 August 2026
Ambu continues our commitment to lowering carbon emissions in accordance with
our near-term SBTi validated targets. Year to date, the CO2e emissions per tonne of
finished goods have been stable. The 9% reduction in energy consumption per tonne
of finished goods is a positive outcome of our energy efficiency measures and
demonstrates a decoupling of energy use from product output. We continue to focus
on targeted energy improvement initiatives and enhanced data collection.
The development in above metrics over the past three years should be viewed in the
context of Ambu’s production cycle. Inventory was built in FY 2022/23 to support
expected growth and subsequently reduced in FY 2023/24, lowering the immediate
need for additional production capacity. In FY 2024/25, investment resumed, and
new production lines were created to support future growth, temporarily affecting
waste recycling and energy intensity metrics. As the operational impact of the rampup moderates, these metrics are normalizing, and the underlying improvement trend
is becoming more visible. Ambu remains focused on translating our sustainability
priorities into measurable operational progress over time.
6
FINANCIAL OUTLOOK 2025/26
For the full year 2025/26, Ambu now expects organic revenue growth of around 10% and EBIT margin of 12-14%. The
updated organic revenue growth guidance reflects slower volume uptake in Anesthesia & Patient Monitoring, which is
now expected to deliver very low-single-digit organic growth for the full year. As the key growth driver, Endoscopy
Solutions maintains its +15% organic growth outlook. The EBIT margin is expected to be toward the high end of the
12-14% guidance range, supported by continued operating leverage and tariff refunds.
Outlook expectations, FY 2025/26
25 Aug 2026
6 May 2026
4 Feb 2026
5 Nov 2025
Organic revenue growth
~10%
10-12%
10-13%
10-13%
+15%
+15%
+15%
+15%
- Anesthesia & Patient Monitoring
Very LSD
LSD
MSD
MSD
2025/26
EBIT margin before special items
12-14%
12-14%
12-14%
12-14%
30 Sep
+40%
+40%
+40%
+40%
Cash conversion
Financial calendar
End of FY
2025/26
2026/27
Exchange rates assumptions, FY
2025/26
25 Aug 2026
6 May 2026
4 Feb 2026
5 Nov 2025
USD/DKK
6.40
6.40
6.35
6.50
MYR/DKK
1.60
1.60
1.60
1.55
MXN/DKK
0.35
0.35
0.35
0.35
CNY/DKK
0.95
0.90
0.90
0.90
GBP/DKK
8.60
8.60
8.60
8.50
5 Nov
Annual report
2025/26
2 Dec
Annual general
meeting 2026
Forward-looking statements
Forward-looking statements, in particular relating to future sales, operating income, and other key financials, are subject to risks and uncertainties.
Various factors, many of which lie outside of Ambu’s control, may cause the realized results to differ materially from the expectations presented in this
earnings release. Such factors include, but are not confined to, changes in market conditions and the competitive situation, changes in demand and
purchasing patterns, fluctuations in foreign exchange and interest rates, as well as general economic, political, and commercial conditions.
Company announcement no. 17 2025/26
|
25 August 2026
7
MANAGEMENT’S STATEMENT
The Board of Directors and the Executive Management have today reviewed and
approved the interim report for Ambu A/S for the period from 1 October 2025 to 30
June 2026. The interim report has not been audited or reviewed by the company’s
independent auditors.
Executive Management
The interim report is presented in accordance with IAS 34 – Interim Financial
Reporting, as adopted by the EU and additional Danish disclosure requirements for
the interim reporting of listed companies.
Britt Meelby Jensen
Henrik Bender
Chief Executive Officer
Chief Financial Officer
In our opinion, the interim financial report for the first nine months of 2025/26 gives
a true and fair view of the Group’s assets, liabilities and financial position at 30 June
2026 and of the results of the Group’s operations and cash flows for the period 1
October 2025 to 30 June 2026. Furthermore, in our opinion, Management’s review
includes a fair account of the development in the activities and financial position of
the Group, as well as a description of the most significant risks and elements of
uncertainty to which the Group is subject.
Board of Directors
Besides what has been disclosed in the quarterly financial report, no changes in the
Group’s most significant risks and uncertainties have occurred, relative to what was
disclosed in the consolidated Annual Report 2024/25.
Jørgen Jensen
Shacey Petrovic
Chair
Vice Chair
Copenhagen, 26 August 2026
Susanne Larsson
Michael Del Prado
Member
Member
Simon Hesse Hoffmann
David Hale
Member
Member
Gry Sahner Gundestrup
Jesper Bartroff Frederiksen
Employee-elected member
Employee-elected member
Jakob Koch
Employee-elected member
Company announcement no. 17 2025/26
|
25 August 2026
8
CONSOLIDATED
FINANCIAL STATEMENTS
Contents
Page 10
Income statement comments
Page 11
Income statement and statement of comprehensive income
Page 12
Cash flow comments
Page 13
Cash flow statement
Page 14
Balance sheet comments
Page 15
Balance sheet
Page 16
Statement of changes in equity
Page 17
Notes to the interim report
Page 18
Quarterly results overview
Company announcement no. 17 2025/26
|
25 August 2026
9
INCOME STATEMENTS COMMENTS
Revenue
EBIT margin
profitable Endoscopy Solutions business, as
well as production efficiencies.
Total revenue in Q3 2025/26 amounted to
DKK 1,640m, corresponding to an organic
growth of 10.3% and a reported growth of
8.8%, compared to Q3 2024/25. The organic
growth was positively impacted by
continued solid growth in Endoscopy
Solutions of 16.0%. Anesthesia & Patient
Monitoring (A&PM) delivered 1.6% growth,
a reflection of high comparable prior-year
numbers, as well as lower volumes on nonexclusive contracts in selected U.S.
accounts.
EBIT margin in Q3 2025/26 was 13.5%,
corresponding to an increase of 2.2% pts,
compared to Q3 2024/25. EBIT margin
benefited slightly from the combined net
effects of FX and tariffs. Overall, the
underlying EBIT margin was positively
impacted by continued operating leverage
from the solid organic growth.
OPEX to revenue
OPEX to revenue in Q3 2025/26 was 46.0%,
corresponding to an improvement of 1.6%
pts, compared to Q3 2024/25. The
improvement was driven by continued
operating scale. Overall, Ambu continues to
have significant potential to realize
operating leverage, however, as previously
communicated, we remain committed to
investing in future growth by allocating
resources to drive organic growth,
particularly within our commercial setup.
Gross margin
Gross margin in Q3 2025/26 was 59.5%,
corresponding to an increase of 0.6% pts,
compared to Q3 2024/25. In general, the
gross margin is expected to increase over
time, influenced by better price governance,
increased revenue share in the more
Net financials
Net financials in Q3 2025/26 were DKK
-18m, in line with the level in Q3 2024/25.
Tax
Tax in Q3 2025/26 amounted to an expense
of DKK -47m, corresponding to an effective
tax rate of 23%.
Depreciation, amortization, and
impairment losses (DA)
DA in Q3 2025/26 was DKK -100m, slightly
higher than in Q3 2024/25.
Revenue
EBIT margin
DKKm
DKKm
12.0%
10.0%
12.0%
10.0%
10.3%
8.6%
2000
1900
13.5%
16.0%
1800
14.0%
7.3%
400
18.0%
11.3%
1700
12.0%
10.0%
10.5%
11.0%
350
300
250
8.0%
1600
10.0%
200
1500
6.0%
8.0%
1400
150
6.0%
4.0%
1300
100
4.0%
1200
2.0%
1,507
1,466
1,558
1,573
1,640
0.0%
1100
1000
Q3
24/25
Q4
24/25
Revenue
Q1
25/26
Q2
25/26
2.0%
170
147
164
173
221
Q3
24/25
Q4
24/25
Q1
25/26
Q2
25/26
Q3
25/26
0.0%
Q3
25/26
0
Organic growth
Company announcement no. 17 2025/26
50
EBIT
|
EBIT margin
25 August 2026
10
INCOME STATEMENT AND STATEMENT OF COMPREHENSIVE INCOME
Interim report for Q3 2025/26
Statement of comprehensive income
Income statement
Q3
Q3
9M
9M
FY
2025/26 2024/25 2025/26 2024/25 2024/25
DKKm
DKKm
Revenue
1,640
1,507
4,771
4,571
6,037
Net profit for the period
Production costs
-665
-620
-1,901
-1,817
-2,404
Gross profit
975
887
2,870
2,754
3,633
Selling and distribution costs
-465
-457
-1,460
-1,333
-1,792
Other comprehensive income:
Items which are moved to the
income statement under certain
conditions
Development costs
-87
-87
-272
-254
-347
Management and administrative
costs
-202
-173
-580
-530
Operating profit (EBIT) b.s.i.
221
170
558
637
784
221
170
558
637
784
Special items
Operating profit (EBIT)
-710
Financial income
6
3
13
11
15
Financial expenses
-24
-13
-58
-43
-44
Profit before tax
203
160
513
605
755
Tax on profit for the period
-47
-37
-118
-111
-146
Net profit for the period
156
123
395
494
609
Earnings per share (EPS)
0.59
0.46
1.49
1.85
2.29
Diluted earnings per share (EPS-D)
0.59
0.46
1.49
1.85
2.28
Q3
Q3
9M
9M
FY
2025/26 2024/25 2025/26 2024/25 2024/25
156
123
395
494
609
31
-138
103
-109
-109
Other comprehensive
income after tax
31
-138
103
-109
-109
Comprehensive income
for the period
187
-15
498
385
500
Translation adj. in foreign
subsidiaries
Earnings per share in DKK
Company announcement no. 17 2025/26
|
25 August 2026
11
CASH FLOW COMMENTS
Cash flow from operating
activities (CFFO)
CFFO in Q3 2025/26 was DKK 331m,
compared to DKK 237m last year. The
higher cash flow was driven by higher
EBITDA and positively impacted by
improvement in working capital.
Free cash flow (FCF) before acquisition
FCF before acquisitions came to DKK 154m
in Q3 2025/26. This was mainly due to solid
operational performance alongside an
improved working capital.
Cash flow from investing
activities (CFFI) before acquisitions
CFFI before acquisitions in Q3 2025/26
was DKK 177m, corresponding to 11% of
revenue. CFFI was primarily driven by R&D
activities, which amounted to DKK 82m, and
when factoring in development costs, less
depreciation and amortization, total R&D
expenditure amounted to DKK 114m.
Cash flow impact of
development costs
Acquisitions of enterprises
and technology
No acquisitions were made in Q3 2025/26.
Cash flow from financing
activities (CFFF)
CFFF in Q3 2025/26 was DKK -141m. This
was related to repurchase of shares, in line
with the share buyback program of up to
DKK 300m from 6 May until no later than 30
Sep. The intention with the acquired shares
Free cash flow
is cancellation.
Cash position
At 30 June 2026, cash and cash equivalents
were DKK 705m, reflecting a decrease of
DKK 161m since 30 September 2025,
mainly driven by the payout of dividends
and share buyback.
Committed undrawn sustainability-linked
credit facilities amounted to DKK 1,000m,
with an additional accordion of DKK
1,000m.
Free cash flow
DKKm, main components in Q3
DKKm, before acquisitions
DKKm
Q3
Q3
2025/26 2024/25
200
180
17
160
140
Development costs
87
87
Depreciation,
amortization, and
impairment losses
-55
-53
Investments
82
65
114
99
-177
120
100
321
-7
80
60
154
40
20
128
130
13
104
154
Q3
24/25
Q4
24/25
Q1
25/26
Q2
25/26
Q3
25/26
0
Cash flow, R&D
EBITDA Change CAPEX1 Other2
in working
capital
Company announcement no. 17 2025/26
EBITDA
|
Change in working capital
CAPEX*
25 August 2026
Other**
Free
cash
flow
Free cash flow
12
CASH FLOW STATEMENT
Interim report for Q3 2025/26
9M
9M
FY
2025/26 2024/25 2024/25
DKKm
Net profit
DKKm
9M
9M
FY
2025/26 2024/25 2024/25
395
494
609
Cash and cash equivalents, end of period,
are composed as follows:
Income taxes
118
111
146
Cash and cash equivalents
206
170
Financial items
45
32
29
Short-term deposits
499
581
671
372
Cash and cash equivalents, end of period
705
751
866
Adjustment for non-cash items:
Depreciation, amortization, and impairment losses
295
275
Share-based payments
21
18
31
Change in working capital
-100
-293
-273
Change in provisions
-1
-2
-9
Interest received
13
11
15
Interest paid
-18
-22
-28
Income tax paid
-76
-82
-101
Cash flow from operating activities
692
542
791
Investment in intangible assets
-265
-196
-267
Investments in tangible assets
-156
-69
-117
Cash flow from investing activities
-421
-265
-384
Free cash flow
271
277
407
Repayment of lease liability
-54
-48
-63
Purchase of treasury shares
-274
11
11
-110
-102
-102
1
1
1
Cash flow from financing activities
-437
-138
-153
Changes in cash and cash equivalents
-166
139
254
Cash and cash equivalents, beginning of period
866
615
615
5
-3
-3
705
751
866
Exercise of options
Dividend paid
Dividend, treasury shares
Translation adjustment of cash and cash equivalents
Cash and cash equivalents, end of period
Company announcement no. 17 2025/26
|
25 August 2026
195
13
BALANCE SHEET COMMENTS
Total assets
At 30 June 2026, total assets were DKK
7,775m, corresponding to an increase of
DKK 100m, compared to 30 September
2025. The development was mainly driven
by an increase of new development
projects, offset by decreased cash and cash
equivalents as a result of dividend payment
and share buyback.
Invested capital
At 30 June 2026, invested capital was DKK
6,042 m, corresponding to an increase of
DKK 326m, compared to 30 September
2025. The increase was driven by
development projects and expansion of
manufacturing sites (PPE).
Total assets
ROIC
ROIC in Q3 2025/26 was 9%, corresponding
to a decline of 1% pts, compared to Q3
2024/25. The decrease was largely
attributable to an increase in invested
capital.
Net interest-bearing debt (NIBD)
At 30 June 2026, NIBD was DKK
-126m, compared to DKK -319m at 30
September 2025. Through the first 9M of
2025/26, Ambu paid dividend of DKK 110m,
completed the share buyback program of
DKK 150m, and initiated a new share
buyback program of DKK 300m, of which
DKK 124m was completed.
Net working capital
At 30 June 2026, net working capital was
DKK 1,326m, corresponding to 21% of
revenue. The current level exceeded the
20% of revenue target slightly, driven
primarily by elevated inventory levels.
Net interest-bearing debt (NIBD) to
EBITDA
At 30 June 2026, NIBD to EBITDA was -0.1x,
compared to -0.3x at 30 September 2025.
Invested capital and ROIC
DKKm
NIBD and gearing
DKKm
12%
8000
DKKm
11%
10%
9%
9%
6,500
8%
7000
500
400
0.3x
300
0.2x
200
0.1x
100
7,000
9%
10%
7500
0.5x
0.4x
6,000
0.0x
6%
6500
5,500
-0.1x
0
-217
-319
-178
-0.2x
4%
6000
5,000
-0.3x
5500
7,396
7,675
7,581
7,606
7,775
2%
5,688
5,716
5,858
5,961
6,042
0%
5000
Q3
24/25
Q4
24/25
Q1
25/26
Q2
25/26
Q3
25/26
Q3
24/25
Q4
24/25
Q1
25/26
|
25 August 2026
Q2
25/26
ROIC
Q3
25/26
-126
-0.1x
-0.1x
-100
-200
-300
-0.3x
-0.4x
4,000
Invested capital
Company announcement no. 17 2025/26
4,500
-0.2x
-0.2x
-140
-400
-0.5x
-500
Q3
24/25
Q4
24/25
NIBD
Q1
25/26
Q2
25/26
Q3
25/26
NIBD to EBITDA
14
BALANCE SHEET
Interim report for Q3 2025/26
Assets
Equity and liabilities
DKKm
Goodwill
30.06.26
30.06.25
30.09.25
DKKm
30.06.26
30.06.25
30.09.25
1,517
1,498
1,497
Share capital
135
135
135
Acquired technologies, trademarks,
and customer relations
313
348
339
Other reserves
6,033
5,770
5,900
Completed development projects
906
1,029
994
Equity
6,168
5,905
6,035
Other, incl. IT software
128
63
100
11
Development projects and other assets in progress
495
296
319
3,359
3,234
3,249
Property, plant, and equipment
717
560
588
Right-of-use assets
585
526
544
Deferred tax assets
45
133
137
Total non-current assets
4,706
4,453
4,518
Inventories
1,202
1,193
1,272
Trade receivables
970
852
834
Other receivables
46
30
40
Income tax receivable
30
16
33
Prepayments
116
101
112
Intangible assets
Derivative financial instruments
705
751
866
Total current assets
3,069
2,943
3,157
Total assets
7,775
7,396
7,675
Cash and cash equivalents
Company announcement no. 17 2025/26
|
25 August 2026
Deferred tax
7
3
Provisions
15
3
19
5
Credit institutions
Lease liabilities
473
459
462
Non-current liabilities
499
477
481
Provisions
6
1
3
Lease liabilities
87
75
80
Trade payables
574
520
572
7
28
56
434
390
448
Current liabilities
1,108
1,014
1,159
Total liabilities
1,607
1,491
1,640
Total equity and liabilities
7,775
7,396
7,675
Income tax
Other payables
15
STATEMENT OF CHANGE IN EQUITY
Interim report for Q3 2025/26
Share
Capital
Reserve for
foreign currency
translation
adjustments
Retained
earnings
Total
Equity 1 October 2025
135
36
5,864
6,035
Net profit for the period
395
395
DKKm
Other comprehensive income for the period
103
103
Total comprehensive income
103
395
498
Share-based payment
21
21
Tax deduction relating to share-based pay
Transactions with the owners:
Purchase of treasury shares
-3
-3
-274
-274
-110
Distributed dividend
-110
Dividend, treasury shares
1
1
Equity 30 June 2026
135
139
5,894
6,168
Equity 1 October 2024
135
145
5,314
5,594
Net profit for the period
494
494
Other comprehensive income for the period
-109
-109
Total comprehensive income
-109
494
385
Share-based payment
18
18
Tax deduction relating to share-based pay
-2
-2
Exercise of options
11
11
Distributed dividend
-102
-102
Dividend, treasury shares
1
1
135
36
5,734
5,905
At the annual general meeting on 4 December 2025, a dividend of
DKK 110m was proposed by the Board of Directors for 2024/25
and approved by the annual general meeting. Total dividends have
been declared and subsequently paid out, less withholding taxes
paid to the Danish Tax Authorities.
On 10 December 2025, Ambu announced a share buyback
program, which was initiated on 29 December 2025 and
completed as of 11 February 2026. Ambu repurchased a total
number of 1,746,034 treasury shares, totaling DKK 150m and
corresponding to an average purchase price of DKK 85.91.
On 6 May 2026, Ambu launched a new share buyback program of
up to DKK 300 million, to be completed by 30 September 2026. As
of 30 June 2026, the company had repurchased 1,963,517 treasury
shares for a total amount of DKK 123.6 million, representing an
average purchase price of DKK 62.9616 per share.
Transactions with the owners:
Equity 30 June 2025
Company announcement no. 17 2025/26
|
25 August 2026
16
NOTES TO THE INTERIM REPORT
Interim report for Q3 2025/26
Note 1 – Basis of preparation of the interim report
The interim report for the period 1 October 2025 to 30 June 2026 is presented in
accordance with IAS 34 – Interim Financial Reporting as adopted by the EU and additional
Danish disclosure requirements for the interim reporting of listed companies.
The accounting principles applied are consistent with the principles applied in the Annual
Report for 2024/25.
Note 2 – Segment information
Ambu is engaged in a single business activity of medical technology solutions for the
global market, and the Group is seen as one operating segment. Ambu's business
consists of research and development of new solutions, which are then manufactured,
marketed, and sold. Except for the sales of the various solutions, all these functional
activities take place and are managed globally on a highly integrated basis. These
individual functional areas are not managed separately.
Note 3 – Revenue
Q3
Q3
9M
9M
FY
2025/26 2024/25 2025/26 2024/25 2024/25
DKKm
Respiratory
514
446
1,502
1,387
1,818
URO, ENT & GI
532
470
1,526
1,368
1,826
Anesthesia
298
304
884
948
1,249
Patient Monitoring
296
287
859
868
1,144
Total revenue by
business groups
1,640
1,507
4,771
4,571
6,037
North America
802
750
2,333
2,306
3,051
Europe
673
612
1,988
1,827
2,405
Rest of World
165
145
450
438
581
1,640
1,507
4,771
4,571
6,037
Total revenue by markets
Note 4 – Contingent assets
On 20 February 2026, the US Supreme Court ruled that the International Emergency
Economic Powers Act (“IEEPA”) does not provide authority to impose tariffs.
Consequently, tariffs imposed under Executive Orders were deemed invalid and
terminated. U.S. Customs and Border Protection (CBP) was instructed to establish a
process for refunding such tariffs under the supervision of the U.S. Court of International
Trade.
Ambu has incurred total IEEPA tariffs of DKK 195m (USD 29.8m), of which DKK 40m (USD
6.1m) was recognized as an expense in the 2024/25 financial year.
As of 30 June 2026, total outstanding refunds amount to DKK 155m. Management has
assessed that the recognition criteria for the outstanding refund claims were not met, as
realization was not considered virtually certain. Accordingly, no receivable has been
recognized in respect of remaining potential refunds. Management will reassess the
matter as further information becomes available.
Received tariff refunds are recognized as a recovery of tariffs and presented consistently
with the original classification of the related tariff expenses.
Subsequent to 30 June 2026, Ambu received additional cash refunds of DKK 85m. As the
refunds were received after the reporting date, the related income has been recognized in
Q4 2025/26.
Note 5 – Contingent liabilities
Ambu is involved in pending litigations, claims, and investigations arising out of the
normal conduct of our business. Ambu’s ongoing operations and the use of Ambu’s
solutions in hospitals and clinics, etc., involve the general risk of claims for damages and
sanctions against Ambu. The risk is deemed to be customary for the industry.
Provisions for probable losses have been made for those matters that Management has
assessed as needed, but there are uncertainties associated with these estimates.
Ambu does not expect any pending litigations, claims, or investigations to have a
material effect on the Group’s financial position.
Note 6 – Subsequent events
Apart from the matters described in this interim report and Note 4, Management is not
aware of any events subsequent to 30 June 2026 which could be expected to have a
significant impact on the Group’s financial position.
Company announcement no. 17 2025/26
|
25 August 2026
17
QUARTERLY RESULTS
Q3
Q2
Q1
Q4
Q3
Q2
Q1
2025/26 2025/26 2025/26 2024/25 2024/25 2024/25 2024/25
DKKm
Revenue by business groups
Respiratory
URO, ENT, & GI
Endoscopy Solutions
Anesthesia
Patient Monitoring
Anesthesia & Patient Monitoring
Total revenue
Production costs
Gross profit
514
532
1,046
298
296
594
501
495
996
290
287
577
487
499
986
296
276
572
431
458
889
301
276
577
446
470
916
304
287
591
469
460
929
326
299
625
472
438
910
318
282
600
1,640
-665
975
1,573
-625
948
1,558
-611
947
1,466
-587
879
1,507
-620
887
1,554
-612
942
1,510
-585
925
Selling and distribution costs
Development costs
Management and administrative costs
Operating profit (EBIT) b.s.i.
-465
-87
-202
221
-496
-91
-188
173
-499
-94
-190
164
-459
-93
-180
147
-457
-87
-173
170
-448
-88
-182
224
-428
-79
-175
243
Special items
Operating profit (EBIT)
221
173
164
147
170
224
243
Financial income
Financial expenses
Profit before tax
6
-24
203
3
-19
157
4
-15
153
4
-1
150
3
-13
160
4
-20
208
4
-10
237
Tax on profit for the period
Net profit for the period
-47
156
-36
121
-35
118
-35
115
-37
123
-20
188
-54
183
59.5
754
46.0
321
60.3
775
49.3
271
60.8
783
50.3
261
60.0
732
49.9
244
58.9
717
47.6
263
60.6
718
46.2
318
61.3
682
45.2
331
19.6
17.2
13.5
-0.1
21
11.0
-0.1
22
16.8
10.5
-0.2
22
16.6
10.0
-0.3
21
17.5
11.3
-0.2
21
20.5
14.4
-0.1
23
21.9
16.1
0.0
22
Key figures and ratios
Gross margin, %
OPEX
OPEX ratio, %
EBITDA before special items
EBITDA margin before special items,
%
EBIT margin before special items, %
NIBD/EBITDA before special items
Net working capital, % of revenue
DKKm
Q3
Q2
Q1
Q4
Q3
Q2
Q1
2025/26 2025/26 2025/26 2024/25 2024/25 2024/25 2024/25
Organic growth, business groups, %
Respiratory
17.1
12.2
8.3
8.8
11.2
8.5
17.7
URO, ENT, & GI
15.0
15.5
21.0
16.0
20.8
18.3
23.9
Endoscopy Solutions
16.0
13.8
14.4
12.4
15.9
13.1
20.6
Anesthesia
-0.4
-4.4
-1.2
6.4
3.9
11.2
17.8
Patient Monitoring
3.6
-0.4
1.1
6.4
9.3
8.2
17.8
Anesthesia & Patient Monitoring
1.6
-2.5
-0.1
6.4
6.4
9.8
17.8
Organic growth, total revenue, %
10.3
7.3
8.6
10.0
12.0
11.7
19.5
Exchange rate effects
-1.5
-6.1
-5.4
-4.3
-3.0
2.0
0.9
Reported growth, total revenue, %
8.8
1.2
3.2
5.7
9.0
13.7
20.4
North America
9.7
6.1
9.8
11.4
12.8
12.4
19.2
Europe
10.2
7.9
9.7
10.2
11.5
13.1
17.1
Rest of World
14.4
10.7
-1.6
1.3
7.9
3.0
28.0
Organic growth, total revenue, %
10.3
7.3
8.6
10.0
12.0
11.7
19.5
Organic growth, geographies, %
Cash flow, DKKm
Cash flow from operating activities
331
255
106
249
237
161
144
Cash flow from investing activities
-177
-151
-93
-119
-109
-81
-75
Free cash flow
154
104
13
130
128
80
69
Cash flow from operating activities
20
16
7
17
16
10
10
Cash flow from investing activities
-11
-9
-6
-8
-8
-5
-5
Free cash flow
9
7
1
9
8
5
5
Cash conversion, % of EBITDA
48
38
5
53
49
25
21
Assets
7,775
7,606
7,380
1,352
7,675
1,238
7,414
1,326
7,581
1,321
7,396
Net working capital
1,266
1,321
1,228
Equity
6,168
6,101
5,914
5,795
-126
-140
6,035
-319
5,905
Net interest-bearing debt (NIBD)
6,036
-178
-217
-86
-24
Invested capital
6,042
5,961
5,858
5,716
5,688
5,828
5,771
Cash flow, % of revenue
Balance sheet
Share-related ratios (in DKK)
Company announcement no. 17 2025/26
|
25 August 2026
Market price per share
61
68
88
93
99
118
104
Earnings per share (EPS)
0.59
0.46
0.44
0.43
0.46
0.71
0.68
Diluted earnings per share (EPS-D)
0.59
0.46
0.44
0.43
0.46
0.71
0.68
18